A consensus statement on the use of IV immunoglobulins in patients with autoimmune mucocutaneous blister diseases has been issued

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.430, 2003-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A consensus statement on the use of biological agents to treat rheumatic diseases has been issued

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 467, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The US FDA has issued a statement on the use of conjugated estrogens/medroxyprogesterone

By  

Inpharma, Vol. 1, Iss. 1359, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Clinical guidance on the use of topical calcineurin inhibitors in atopic dermatitis has been issued

By  

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Clinical guidance on the use of topical calcineurin inhibitors in atopic dermatitis has been issued

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 470, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases

By  

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3166-3175

Bentham Science Publishers

Access to resources Recommend Favorite